Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by Hempdocon May 30, 2020 1:03pm
116 Views
Post# 31091933

RE:Lancet 'study' not holding up to scrutiny

RE:Lancet 'study' not holding up to scrutiny
Quattro74 wrote: Scientists from arround the world, in cluding statisticians, are asking to see the data behind the Lancet 'study' which sugested HCQ was harmful.


Yep...lots of questions re: the statistical/data integrity of the Lancet study.  Were the comparison groups (HCQ or no HCQ) truly balanced?  Don't appear to be...HCQ patients may have been more ill.
And what were the dosages of HCQ used in this very sick population?  Probably much higher than 2400 mg.

This study's conclusions should be withdrawn shortly, & the WHO was irresponsible in accepting it so readily in the first place...before any independent verification(s).  This study as a whole was frankly misguided (solely looking at very sick inpatients).  Intended or not, it attempts to paint HCQ with a broad brush in hopes of discrediting it...JMO.  Interestingly, the study served to discredit itself.  I am looking forward to more promising outpatient data.
Bullboard Posts